Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Retrospective Observational Study of the Safety and Toxicity Management of Abemaciclib in Combination with Adjuvant Hormone Therapy in Patients with RH+ ,HER2-nonoveramplified Breast Cancer, Real-life Data

NCT06621459 is registered in ClinicalTrials.gov with University Hospital, Brest as lead sponsor.

NCT NCT06621459
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06621459 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Retrospective Observational Study of the Safety and Toxicity Management of Abemaciclib in Combination with Adjuvant Hormone Therapy in Patients with RH+ ,HER2-nonoveramplified Breast Cancer, Real-life Data
Lead sponsor
University Hospital, Brest
Phase
Observational
Overall status
Recruiting
Start date
September 26, 2024
Completion date
October 31, 2025
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

abemaciclib, adjuvant therapy, antineoplastic combined chemotherapy protocols, breast neoplasms, brest cancer